News | December 02, 2023
Venus Remedies granted market authorizations in Saudi Arabia and Philippines
These regulatory approvals signify a significant milestone for Venus Remedies Limited
These regulatory approvals signify a significant milestone for Venus Remedies Limited
Norgestrel and Ethinyl Estradiol Tablets USP (RLD: Lo/Ovral-28) had estimated annual sales of US $33 million in the US
The product has been in-licensed from Strides and will be commercialized by Amneal
The product is expected to be launched in FY25
South Asia’s largest Trade Fair for pharma brought together over 50,000 visitors from across the globe, more than 1,500 exhibitors showcasing 10,000+ products and representation from over 80 countries
Equipped with most advanced Distributed Control System (DCS) automation technology, the facility has been set up with an investment of Rs. 200 crore
Canagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor
This approval showcases Teva’s proven strengths in complex generic formulations development and device engineering
Extraintestinal pathogenic E. coli (ExPEC) has been identified as the leading bacterial cause of sepsis
Reports revenue growth of 9% to INR 882 crores in Q2 FY24
Subscribe To Our Newsletter & Stay Updated
